Finch Therapeutics Group, Inc. (FNCH)

OTCMKTS: FNCH · Delayed Price · USD
1.560
+0.010 (0.65%)
Jul 19, 2024, 12:06 PM EDT - Market closed
Market Cap 2.50M
Revenue (ttm) 2.85M
Net Income (ttm) -16.28M
Shares Out 1.61M
EPS (ttm) -10.14
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 100
Open 1.565
Previous Close 1.550
Day's Range 1.560 - 1.565
52-Week Range 0.800 - 9.420
Beta 0.41
Analysts n/a
Price Target n/a
Earnings Date May 10, 2024

About FNCH

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn’s disease; and other microbiome product candidates. The company has collaboratio... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Mar 19, 2021
Employees 1
Stock Exchange OTCMKTS
Ticker Symbol FNCH
Full Company Profile

Financial Performance

In 2023, FNCH's revenue was $107,000, a decrease of -87.57% compared to the previous year's $861,000. Losses were -$74.75 million, -34.25% less than in 2022.

Financial Statements

News

Finch Announces Reverse Stock Split of Common Stock

BOSTON, June 09, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch”, “Finch Therapeutics” or the “Company”) (Nasdaq: FNCH), a microbiome technology company with a portfolio of intellectu...

1 year ago - GlobeNewsWire

Finch Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates

SOMERVILLE, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch”, “Finch Therapeutics” or the “Company”) (Nasdaq: FNCH), a microbiome technology company with a portfolio of ...

1 year ago - GlobeNewsWire

Finch Therapeutics Announces Clinical Collaboration in Ulcerative Colitis with Brigham and Women's Hospital and Updates to University of Minnesota License Agreement

SOMERVILLE, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch”, “Finch Therapeutics” or the “Company”) (Nasdaq: FNCH), a microbiome technology company with a portfolio o...

1 year ago - GlobeNewsWire

Finch Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

SOMERVILLE, Mass., March 23, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch”, “Finch Therapeutics” or the “Company”) (Nasdaq: FNCH), a microbiome technology company with a portfolio o...

1 year ago - GlobeNewsWire

Finch Therapeutics Announces Decision to Discontinue Phase 3 Trial of CP101 and Focus on Realizing the Value of Its Intellectual Property Estate and Other Assets

SOMERVILLE, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (the “Company,” “Finch,” or “Finch Therapeutics”) (Nasdaq: FNCH) today announced its decision to discontinue the PRI...

1 year ago - GlobeNewsWire

Finch Therapeutics Provides Corporate Updates and Reports Third Quarter 2022 Financial Results

SOMERVILLE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Hu...

1 year ago - GlobeNewsWire

Finch Therapeutics to Present at the Jefferies London Healthcare Conference and Evercore ISI HealthCONx Conference

SOMERVILLE, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Hu...

1 year ago - GlobeNewsWire

Finch Therapeutics Regains Full Rights to FIN-524 and FIN-525 Targeted Microbiome Product Candidates in Development for IBD

SOMERVILLE, Mass., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Hu...

2 years ago - GlobeNewsWire

Finch Therapeutics to Participate in Upcoming June Investor Conferences

SOMERVILLE, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Hu...

2 years ago - GlobeNewsWire

Finch Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results

SOMERVILLE, Mass., May 16, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Hum...

2 years ago - GlobeNewsWire

Finch Therapeutics to Host Corporate Update Conference Call and Webcast on May 16, 2022

SOMERVILLE, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Hum...

2 years ago - GlobeNewsWire

Finch Therapeutics Announces Removal of FDA Clinical Hold on CP101 IND

SOMERVILLE, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its H...

2 years ago - GlobeNewsWire

Finch Therapeutics Announces Workforce Restructuring to Focus Resources on Key Development Programs

SOMERVILLE, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its H...

2 years ago - GlobeNewsWire

Finch Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates

SOMERVILLE, Mass., March 31, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its H...

2 years ago - GlobeNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Finch Therapeutics Group, Inc. - FNCH

NEW YORK , March 26, 2022 /PRNewswire/ --Pomerantz LLP is investigating claims on behalf of investors of Finch Therapeutics Group, Inc. ("Finch" or the "Company") (NASDAQ: FNCH).  Such investors are a...

2 years ago - PRNewsWire

See Why Did Finch Therapeutics Halt Enrolment In Late-Stage C. Difficile Infection Trial

The FDA has issued a clinical hold letter to Finch Therapeutics Group Inc's (NASDAQ: FNCH) PRISM4 Phase 3 trial of CP101 in recurrent C. difficile infection (CDI).

2 years ago - Benzinga

Finch Therapeutics Provides an Update on its Phase 3 Trial of CP101 in Recurrent C. difficile Infection

SOMERVILLE, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics” or “Company”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company lev...

2 years ago - GlobeNewsWire

Finch Therapeutics to Participate in the Chardan Metagenomics and Microbiome Medicines Summit

SOMERVILLE, Mass., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Hu...

2 years ago - GlobeNewsWire

Finch Therapeutics Announces Additions to Senior Leadership Team

SOMERVILLE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Hu...

2 years ago - GlobeNewsWire

Finch Therapeutics Further Strengthens Patent Portfolio with Two New U.S. Patents Granted for FIN-211, an Investigational Microbiome Therapeutic in Development for Autism Spectrum Disorder

SOMERVILLE, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Hu...

2 years ago - GlobeNewsWire

Finch Therapeutics Appoints Joseph Vittiglio, JD, as Chief Business and Legal Officer

SOMERVILLE, Mass., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Hu...

2 years ago - GlobeNewsWire

Finch Therapeutics' C. Difficile Infection Candidate Meets Primary Goal In Mid-Stage Study

Finch Therapeutics Group Inc (NASDAQ: FNCH) announced positive topline results from PRISM-EXT, an open-label extension of the PRISM3 Phase 2 trial evaluating CP101 to prevent recurrent C. difficile in...

2 years ago - Benzinga

Finch Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates

SOMERVILLE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Hu...

2 years ago - GlobeNewsWire

Finch Therapeutics Announces Transition of Chief Medical Officer

SOMERVILLE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Hu...

2 years ago - GlobeNewsWire

Finch Therapeutics Announces Positive Topline Results from PRISM-EXT Phase 2 Trial of CP101 for Prevention of Recurrent C. difficile Infection

SOMERVILLE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Hu...

2 years ago - GlobeNewsWire